Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 12:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SOM230 Clear all
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

NCT00698464
View directory record Official record
Conditions
Hepatic Cirrhosis, Alcoholism
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 17, 2026, 12:48 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

NCT00929669
View directory record Official record
Conditions
Gonadotroph Adenomas
Interventions
pasireotide LAR
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 1 Interventional

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

NCT00446082
View directory record Official record
Conditions
Carcinoid Tumor, Acromegaly
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Stanford, California • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 17, 2026, 12:48 PM EDT
Approved For Marketing No phase listed Expanded access

An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly

NCT01995734
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide long acting release formulation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
37
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 2 Interventional

A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease

NCT00088608
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
SOM230 s.c.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 17, 2026, 12:48 PM EDT
Terminated Phase 2 Interventional Results available

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

NCT01313559
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer, Chemotherapy Naive Prostate Cancer, Prostate Cancer
Interventions
Pasireotide, Everolimus, Laboratory biomarker analysis
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 2 Interventional Results available

Pasireotide LAR in Severe Polycystic Liver Disease

NCT01670110
View directory record Official record
Conditions
Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney Disease, Autosomal Dominant Polycystic Liver Disease
Interventions
Pasireotide LAR, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 2 Interventional

Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

NCT00088582
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide (SOM230), Octreotide (Sandostatin)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

NCT00434148
View directory record Official record
Conditions
Cushing's Disease
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
10
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Sep 17, 2026, 12:48 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma

NCT00813592
View directory record Official record
Conditions
Cancer
Interventions
SOM230B
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 2 Interventional Results available

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

NCT01253161
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoid Tumors
Interventions
Pasireotide Long Acting Release (LAR)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
2
States / cities
Stanford, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

NCT00690430
View directory record Official record
Conditions
Symptomatic Refractory Resistant Carcinoid Disease
Interventions
Pasireotide, Octreotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Loma Linda, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 17, 2026, 12:48 PM EDT
Withdrawn Phase 2 Interventional

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

NCT01329289
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma
Interventions
SOM230, Bortezomib, Dexamethasone
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

NCT01364415
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Pasireotide LAR
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 2 Interventional Results available

Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer

NCT01270321
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Everolimus, Pasireotide, Everolimus and Pasireotide
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 17, 2026, 12:48 PM EDT
Withdrawn Phase 2 Interventional

SOM230 Ectopic ACTH-producing Tumors

NCT02780882
View directory record Official record
Conditions
Ectopic ACTH Syndrome
Interventions
Pasireotide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 2 Interventional Results available

Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

NCT01488487
View directory record Official record
Conditions
Advanced Adult Hepatocellular Carcinoma
Interventions
Everolimus, Pasireotide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Tampa, Florida • Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 2 Interventional Results available

Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease

NCT00171951
View directory record Official record
Conditions
Cushing Disease
Interventions
Pasireotide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
3
States / cities
Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 17, 2026, 12:48 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

NCT02619617
View directory record Official record
Conditions
Cluster Headache - Episodic and Chronic
Interventions
SOM230, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Culver City, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma

NCT01639352
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
SOM230
Biological
Lead sponsor
Lynn Feun
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Sep 17, 2026, 12:48 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

NCT00088595
View directory record Official record
Conditions
Carcinoid Tumors
Interventions
Pasireotide (SOM230)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced Sep 17, 2026, 12:48 PM EDT
Completed Phase 1 Interventional

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

NCT00804336
View directory record Official record
Conditions
Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
Interventions
SOM230, RAD001
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Sep 17, 2026, 12:48 PM EDT